Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

113.13 +4.90 (+4.53%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biontech Se ADR

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
65 66 Next >
Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine
From Pfizer Inc.
Via Business Wire
Moderna Claims Pfizer, BioNTech Stole Its Patented Tech In Covid Shot
The lawsuit alleges Comirnaty violates Moderna's patents from 2010-16. 
Via Investor's Business Daily
Moderna Entangles Pfizer/BioNTech In COVID-19 Vaccine Patent Lawsuits: All You Need To Know
Moderna Inc (NASDAQ: MRNA) has  
Via Benzinga
Pfizer And Moderna Are In A Race With Omicron; Will The Vaccine Stocks Be Too Late?
The companies hope to launch updated boosters this fall. This is what experts think of their prospects. 
Via Investor's Business Daily
BioNTech Whale Trades For August 09
  A whale with a lot of money to spend has taken a noticeably bullish stance on BioNTech. Looking at options history for BioNTech (NASDAQ:BNTX) we detected 10 strange trades. 
Via Benzinga
AstraZeneca's CEO Says There Are No COVID Regrets, Looks For Oncology Acquisitions
In a Reuters report, AstraZeneca Plc's (NASDAQ: 
Via Benzinga
Moderna Asks FDA To Sign Off On Its Updated Covid Booster Shot
Moderna put the finishing touches on its FDA filing Tuesday, trailing its rivals by a day. 
Via Investor's Business Daily
Pfizer/BioNTech's COVID-19 Vaccine Updated Data Shows Around 76% Efficacy In Toddlers
Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have  
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Boosters Are Coming For Dangerous Omicron COVID-19 Variant. Here's Who May Be Rolling Them Out
Via Benzinga
Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age
From Pfizer Inc.
Via Business Wire
Face Of US COVID-19 Response, Dr Anthony Fauci To Retire In December
  
Via Benzinga
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
Benzinga Before The Bell: Apple Employees Resist Calls For Return-To-Office, Tesla About To Hike FSD Prices Again, MGM China Injects $594M Into Macau Unit And Other Top Financial Stories Monday, August 22
Reuters Vodafone To Sell Hungarian Business For $1.8B: Report 
Via Benzinga
Canada OKs Pfizer COVID-19 Booster For Kids Aged 5-11 Years
Via Benzinga
Covid Stocks Pfizer, Moderna, Novavax Face Their Next Challenge, And It's Worth Billions
How they handle an upcoming shift in payments will be telling for their tailwind. 
Via Investor's Business Daily
Biden Administration To Stop Purchasing COVID-19 Solutions By End Of 2022
Via Benzinga
7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher
These monkeypox stocks could be among the best choices to buy in August. Each can make great investments as government responses ramp up. 
Via InvestorPlace
A Look Into Healthcare Sector Value Stocks
  Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base... 
Via Benzinga
Landmark Drug Pricing Reform Bill Passes Congress House
The U.S. House of Representatives voted 220-207 to pass new, wide-ranging legislation allowing Medicare drug price negotiations for the first time and capping seniors’ drug expenses to $2,000 per year... 
Via Benzinga
Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review
The major indexes continued to advance, despite some key warnings. 
Via Investor's Business Daily
Pharmaceutical Companies Report Gearing Up To Combat COVID Variants This Fall
The more contagious omicron BA.4 and BA.5 COVID-19 variants are dominant in all parts of the United States, making up more than 70% of infections.  
Via Benzinga
Global Multiple Sclerosis Drugs Market Size Projected To Reach $33 Billion By 2029
Palm Beach, FL –– August 11, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by... 
Via FinancialNewsMedia
Exposures COVID-19
Twitter To $50? Here Are 5 Other Price Target Changes For Wednesday
Wedbush boosted the price target on Twitter, Inc. (NYSE: TWTR) from $30 to $50. Wedbush analyst Daniel Ives maintained the stock with a Neutral rating. Twitter shares rose 3.4% to $44.29 in pre-market... 
Via Benzinga
7 Blue-Chip Stocks That Will Survive 2022
These are among the best blue-chip stocks to buy now. Here's why ABBV, BDX, CI, DD, MMM, JPM, and PFE can make great investments. 
Via InvestorPlace
Fear & Greed Index Remains In 'Neutral' Zone As Investors Await Wednesday's Inflation Report
The U.S. stock markets remained in the "neutral" zone on Tuesday, according to the CNN Money Fear and Greed index. Wall Street closed mixed on Friday after a New York Federal Reserve survey showed U.S.... 
Via Benzinga
Here's What's Going On With Novavax Shares
Novavax, Inc. (NASDAQ: NVAX) shares are trading lower by 3.05% to $58.43 Monday afternoon in sympathy with BioNTech SE - ADR (NASDAQ: BNTX), which reported worse-than-expected second-quarter results. 
Via Benzinga
Why Moderna Shares Are Falling Following BioNTech's Earnings Results
Moderna Inc (NASDAQ: MRNA) shares are trading lower by 2.32% to $182.50 Monday afternoon in sympathy with BioNTech SE - ADR (NASDAQ: BNTX), which reported worse-than-expected second-quarter results. 
Via Benzinga
Why These Pfizer Analysts Like The Global Blood Therapeutics Deal
Pfizer Inc. (NYSE: PFE) shares were trading lower Monday after the drugmaker announced a $5.4-billion bid to acquire blood disorder drugmaker Global Blood Therapeutics Inc (NASDAQ: GBT). 
Via Benzinga
Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday
Gainers Helbiz, Inc. (NASDAQ: HLBZ) jumped 114.6% to close at $1.61 on Monday after climbing over 27% on Friday. 
Via Benzinga
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.